The Industry’s Definitive Meeting to Advance the Development of Clinically Transformative Neuropsychiatric Drugs
With the huge unmet clinical need in neuropsychiatry and despite multiple approved pharmaceuticals available, the development of the next generation of neuropsychiatric drugs is essential.
Historically, drug development within neuropsychiatry has been stifled for decades by a lack of scientific progress in the neuropsychiatric field combined with costly and challenging clinical trials.
The abundance of excitement and scientific progress in the field – especially with the recent approval of esketamine – will be captured at the NPD meeting, as well as unravelling the complexities of developing truly transformative neuropsychiatric drugs.
With 70+ of the field’s thought-leaders uniting from around the world, NPD will be your opportunity to not only gather the latest scientific insights but to discuss, in depth, the challenges that have been stifling the progress of neuropsychiatric drug development such as translatable models, biomarkers and looking to target neuropsychiatry symptomatically.
Join us at NPD to stride towards developing neuropsychiatric drugs to truly transform patient quality of care.
Other Events in the CNS Series:
What previous NPD attendees had to say:
“Excellent conference with a very good and diverse set of speakers and topics”
Jim Cassella, Chief Development Officer, Concert Pharmaceuticals
“Very good conference”
Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp.